Ditchcarbon
  • Contact
  1. Organizations
  2. Epizyme, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 22 days ago

Epizyme, Inc. Sustainability Profile

Company website

Epizyme, Inc., a pioneering biopharmaceutical company headquartered in the United States, is at the forefront of developing innovative therapies for cancer and other serious diseases. Founded in 2008, Epizyme has made significant strides in the field of epigenetics, focusing on the discovery and development of small molecule drugs that target specific genetic mutations. The company’s flagship product, Tazemetostat, is a first-in-class EZH2 inhibitor that has garnered attention for its unique mechanism of action and potential to treat various malignancies. With a strong commitment to advancing precision medicine, Epizyme has established a notable market position, particularly in the oncology sector, and continues to expand its pipeline of targeted therapies. Through its dedication to scientific excellence, Epizyme is shaping the future of cancer treatment and improving patient outcomes.

DitchCarbon Score

How does Epizyme, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

83

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Epizyme, Inc.'s score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.

89%

Let us know if this data was useful to you

Epizyme, Inc.'s reported carbon emissions

Inherited from Ipsen S.A.

Epizyme, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Ipsen S.A., which means that any climate commitments or emissions data may be inherited from its parent organisation. As a subsidiary, Epizyme's climate initiatives and targets are aligned with those of Ipsen S.A. However, specific reduction targets or achievements for Epizyme itself have not been disclosed. The company does not have any documented reduction targets or climate pledges at this time. For context, Ipsen S.A. has established various climate initiatives, which may influence Epizyme's approach to sustainability and emissions management. As of now, Epizyme's commitment to addressing climate change remains vague, with no specific metrics or targets available for public review.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20192021202220232024
Scope 1
14,316,000
00,000,000
00,000,000
00,000,000
0,000,000
Scope 2
4,343,000
0,000,000
0,000,000
000,000
000,000
Scope 3
121,718,000
00,000,000
00,000,000
-
00,000,000

How Carbon Intensive is Epizyme, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Epizyme, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Epizyme, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Epizyme, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Epizyme, Inc.'s Scope 3 Categories Breakdown

Epizyme, Inc.'s Scope 3 emissions, which increased by 405% last year and decreased by approximately 25% since 2019, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 67% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
67%
Capital Goods
8%
Business Travel
8%
Upstream Transportation & Distribution
6%
Fuel and Energy Related Activities
4%
Employee Commuting
3%
Waste Generated in Operations
3%
Upstream Leased Assets
<1%
Downstream Transportation & Distribution
<1%
End-of-Life Treatment of Sold Products
<1%

Epizyme, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Epizyme, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Epizyme, Inc.'s Emissions with Industry Peers

Forma Therapeutics Holdings, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 days ago

Spectrum Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 27 days ago

Celgene Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 21 days ago

Otsuka Pharmaceutical

JP
•
Pharmaceutical Preparation Manufacturing
Updated about 14 hours ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated about 12 hours ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.5
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy